Product Code: DIEI1050
DelveInsight's 'Diabetic Macular Disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Macular Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017-2030
Diabetic Macular Disease Understanding
The DelveInsight Diabetic Macular Disease epidemiology report gives a thorough understanding of the Diabetic Macular Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Diabetic Macular Disease in the US, Europe, and Japan. The report covers the detailed information of the Diabetic Macular Disease epidemiology scenario in seven major countries (US, EU5, and Japan).
Diabetic Macular Disease Epidemiology Perspective by DelveInsight
The Diabetic Macular Disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Diabetic Macular Disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Diabetic Macular Disease epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Diabetic Macular Disease Detailed Epidemiology Segmentation
The Diabetic Macular Disease epidemiology covered in the report provides historical as well as forecasted Diabetic Macular Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Diabetic Macular Disease report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report:
- The Diabetic Macular Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Diabetic Macular Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Macular Disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Diabetic Macular Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Macular Disease
- The report provides the segmentation of the Diabetic Macular Disease epidemiology
Report Highlights:
- 11-Year Forecast of Diabetic Macular Disease epidemiology
- 7MM Coverage
- Total Cases of Diabetic Macular Disease
- Total Cases of Diabetic Macular Disease according to segmentation
- Diagnosed cases of Diabetic Macular Disease
KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Macular Disease?
- What are the key findings pertaining to the Diabetic Macular Disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Diabetic Macular Disease across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Diabetic Macular Disease?
- What are the currently available treatments of Diabetic Macular Disease?
Reasons to buy:
- The Diabetic Macular Disease Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Diabetic Macular Disease market
- Quantify patient populations in the global Diabetic Macular Disease market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Diabetic Macular Disease therapeutics in each of the markets covered
- Understand the magnitude of Diabetic Macular Disease population by its epidemiology
- The Diabetic Macular Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Table of Contents
1. Key Insights
2. Executive Summary of Diabetic Macular Disease
3. Diabetic Macular Disease : Disease Background and Overview
- 3.1. Introduction
- 3.2. Sign and Symptoms
- 3.3. Pathophysiology
- 3.4. Risk Factors
- 3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
- 5.1. Epidemiology Key Findings
- 5.2. Assumptions and Rationale: 7MM
- 5.3. Epidemiology Scenario: 7MM
- 5.3.1. Diabetic Macular Disease Epidemiology Scenario in the 7MM (2017- 2030)
- 5.4. United States Epidemiology
- 5.4.1. Diabetic Macular Disease Epidemiology Scenario in the United States (2017- 2030)
- 5.5. EU-5 Country-wise Epidemiology
- 5.5.1. Germany Epidemiology
- 5.5.1.1. Diabetic Macular Disease Epidemiology Scenario in Germany (2017- 2030)
- 5.5.2. France Epidemiology
- 5.5.2.1. Diabetic Macular Disease Epidemiology Scenario in France (2017- 2030)
- 5.5.3. Italy Epidemiology
- 5.5.3.1. Diabetic Macular Disease Epidemiology Scenario in Italy (2017- 2030)
- 5.5.4. Spain Epidemiology
- 5.5.4.1. Diabetic Macular Disease Epidemiology Scenario in Spain (2017- 2030)
- 5.5.5. United Kingdom Epidemiology
- 5.5.5.1. Diabetic Macular Disease Epidemiology Scenario in the United Kingdom (2017-2030)
- 5.6. Japan Epidemiology
- 5.6.1. Diabetic Macular Disease Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
- 6.1. Diabetic Macular Disease Treatment and Management
- 6.2. Diabetic Macular Disease Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
- 9.1. Bibliography
- 9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
The table of contents is not exhaustive; will be provided in the final report
List of Tables
- Table 1: Diabetic Macular Disease Epidemiology in 7MM (2017-2030)
- Table 2: Diabetic Macular Disease Diagnosed and Treatable Cases in 7MM (2017-2030)
- Table 3: Diabetic Macular Disease Epidemiology in the United States (2017-2030)
- Table 4: Diabetic Macular Disease Diagnosed and Treatable Cases in the United States (2017-2030)
- Table 5: Diabetic Macular Disease Epidemiology in Germany (2017-2030)
- Table 6: Diabetic Macular Disease Diagnosed and Treatable Cases in Germany (2017-2030)
- Table 7: Diabetic Macular Disease Epidemiology in France (2017-2030)
- Table 8: Diabetic Macular Disease Diagnosed and Treatable Cases in France (2017-2030)
- Table 9: Diabetic Macular Disease Epidemiology in Italy (2017-2030)
- Table 10: Diabetic Macular Disease Diagnosed and Treatable Cases in Italy (2017-2030)
- Table 11: Diabetic Macular Disease Epidemiology in Spain (2017-2030)
- Table 12: Diabetic Macular Disease Diagnosed and Treatable Cases in Spain (2017-2030)
- Table 13: Diabetic Macular Disease Epidemiology in the United Kingdom (2017-2030)
- Table 14: Diabetic Macular Disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
- Table 15: Diabetic Macular Disease Epidemiology in Japan (2017-2030)
- Table 16: Diabetic Macular Disease Diagnosed and Treatable Cases in Japan (2017-2030)
List of Figures
- Figure 1: Diabetic Macular Disease Epidemiology in 7MM (2017-2030)
- Figure 2: Diabetic Macular Disease Diagnosed and Treatable Cases in 7MM (2017-2030)
- Figure 3: Diabetic Macular Disease Epidemiology in the United States (2017-2030)
- Figure 4: Diabetic Macular Disease Diagnosed and Treatable Cases in the United States (2017-2030)
- Figure 5: Diabetic Macular Disease Epidemiology in Germany (2017-2030)
- Figure 6: Diabetic Macular Disease Diagnosed and Treatable Cases in Germany (2017-2030)
- Figure 7: Diabetic Macular Disease Epidemiology in France (2017-2030)
- Figure 8: Diabetic Macular Disease Diagnosed and Treatable Cases in France (2017-2030)
- Figure 9: Diabetic Macular Disease Epidemiology in Italy (2017-2030)
- Figure 10: Diabetic Macular Disease Diagnosed and Treatable Cases in Italy (2017-2030)
- Figure 11: Diabetic Macular Disease Epidemiology in Spain (2017-2030)
- Figure 12: Diabetic Macular Disease Diagnosed and Treatable Cases in Spain (2017-2030)
- Figure 13: Diabetic Macular Disease Epidemiology in the United Kingdom (2017-2030)
- Figure 14: Diabetic Macular Disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
- Figure 15: Diabetic Macular Disease Epidemiology in Japan (2017-2030)
- Figure 16: Diabetic Macular Disease Diagnosed and Treatable Cases in Japan (2017-2030)
The table of contents is not exhaustive; will be provided in the final report
